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transcriptional events, including not only its named fact, a survey of OMIM reveals that of the human genetic
function as a coactivator for the phosphorylated form diseases for which genes are identified, only a small
of CREB (cAMP response element±binding protein), but minority are caused by mutations in genes encoding
also the regulation of histone acetylation. Yet while inhi- transcription factors. While the restricted focus of this
bition of expression of a C. elegans CBP homolog results work on transcription factors is pragmatic, it is also thus
in a complete absence of somatic morphogenesis, intra- somewhat contrived. For example, the text describes
genic mutations in human CBP are associated with a the involvement of the MSX2 homeobox gene in Boston-
comparatively restricted phenotype, Rubinstein-Taybi type craniosynostosis, a disorder characterized by pre-
syndrome, a dysmorphosis characterized by specific mature fusion of the sutures of the newborn skull. The
limb and craniofacial defects and mental retardation. more frequent and better-characterized craniosynos-
Since these genes are members of multigene familiesÐ tosis syndromes, however, are due to mutations in three
CBP shares homology with another coactivator, P300, of the FGF receptor genes. Left unexplored is what rela-
while XH2 is a member of the helicase superfamilyÐtheir tion, if any, exists between FGF signaling and MSX2 in
restricted mutant phenotypes might be explained on the sutural biology. Ideally, the molecular function of tran-
basis of functional redundancy. What seems equally scription factors is best understood in the context of
likely, howeverÐif unpleasantly more complexÐis that their biologic function, and vice versa.
it is the function of the gene product in the context of Currently, the number of human genetic diseases
the specific biology of the organism that dictates listed in OMIM exceeds 10,000. As more and more dis-
whether and what identifiable phenotype will result. ease-producing genes are identified, an attractive pros-
Interestingly, Rubinstein-Taybi syndrome has been pect for the future is their integrationÐwhether they
associated at low frequency with a variety of other con- encode transcription factors or notÐinto specific path-
genital malformations, raising the possibility that the ways based on the analysis of their respective mutant
phenotypic expression of this disease results from poly- phenotypes. Of course, studies in humans are necessar-
morphic differences in the expression levels of other ily limited in their potential for embryologic and genetic
genes whose products interact with CBP. In the future, investigation, but they do provide a powerful starting
it can be anticipated that the identification of disease point. Although this book is useful, left unconnected for
producing genes that must interact in specific allelic the moment is the link between its first and second
combinations to produce morbid phenotypes will further sections, between molecular function and an under-
underscore the utility of the human as a model organism standing of organismal function. At present, these sec-
for understanding complex polygenic traits, such as in- tions can only cross-refer to one another. One can imag-
telligence, blood pressure, and disease susceptibility. ine, however, that future editions will begin to bridge
What are the practical consequences of the continued this gap.
delineation of human transcription factor diseases? A
potential answer is provided in the book's last chapter,
Richard Maas
entitled ªEpigenetic Mechanisms.º This chapter deals
Genetics Divisionwith the well-known propensity of teratogens such as
Department of Medicineretinoic acid and ethanol to induce congenital birth de-
Brigham and Women's Hospital andfects that phenotypically resemble those observed in
Harvard Medical Schoolsome transcription factor diseases. Although their ter-
Boston, Massachusetts 02115atogenic mechanisms are poorly understood, the idea
that epigenetic factors converge on basic transcriptional
regulatory pathways during fetal development is highly
attractive. Studies have shown, for example, that prena-
tal folate significantly reduces the incidence of neural DNA Repair in the 1990s
tube defects such as spina bifida and anencephaly; as
a result, the U.S. Food and Drug Administration now
DNA Damage and Repairrequires fortification of enriched grain foods with folic
Volume 1: DNA Repair in Prokaryotes and Lower Eu-acid. Provocatively, a mouse mutant deficient for the
karyoteshomeodomain transcription factor Cart1 exhibits anen-
Volume 2: DNA Repair in Higher Eukaryotescephaly, and the incidence of this neural tube defect
Edited by Jac A. Nickoloff and Merl F. Hoekstrais also strongly suppressed by prenatal folate. Thus,
Totowa, NJ: Humana Press (1998). Vol. 1, 626 pp.knowledge of the transcriptional regulatory pathways
$125.00; Vol. 2, 639 pp. $125.00that govern human development may someday make it
possible to understand how factors such as folate work,
A Dallas Cowboys linebacker intercepted a pass as aand to devise new strategies for the prevention of birth
rookie and he made his second interception a decadedefects.
later. When he was asked to comment about this longAnother question, encouraged by the book's title, is
hiatus between the two interceptions he is reported towhether mutations in genes encoding transcription fac-
have said that everyone was entitled to an off decade.tors are any more likely to cause developmental malfor-
It appears that the field of DNA repair followed themation syndromes than genes encoding other factors.
same philosophy. After several momentous discoveries,In the preface, the author implies that this might be
which laid the foundation of the discipline in the 1960s,so, since transcription factors in general are thought to
the repair community had an off decade lasting fromregulate the expression of multiple downstream genes.
about 1968 until 1977. In the 1960s the first known repairYet the same argument can be made about the signal
transduction pathways that growth factors activate. In pathways were characterized, and it was shown that
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DNA repair not only operates in humans but protects us most seriously, the two-volume set artificially and arbi-
trarily divides the field into DNA Repair in Prokaryotesfrom cancer. The later 1970s saw the initial application
of recombinant DNA technology to the field and the and Lower Eukaryotes (Volume 1) and DNA Repair in
Higher Eukaryotes (Volume 2). Such a division, whichdiscovery of the next of what would be a succession of
novel DNA repair pathways. Since then the field has has dogged the repair field for many years, has led to
several anomalies in this book. Thus, as a consequencebeen steadily gaining momentum, and the accomplish-
ments in recent years have been phenomenal. Not sur- of this arbitrary division, C. elegans, X. laevis, and higher
plants have become lower eukaryotes while the quintes-prisingly, DNA repair was chosen ªMolecule of the Yearº
in 1994. In my, not necessarily unbiased, opinion DNA sential prokaryotic repair enzyme, photolyase, which
has been best characterized in E. coli, is in the volumerepair should be declared ªMolecule of the Decadeº for
the 1990s. on repair in higher eukaryotes. These idiosyncratic as-
pects of the book would have been considered harmlessIn the 1990s the molecular (and in certain instances
even the quantum chemical) mechanisms of all major if it were not for the fact that such a division has ham-
pered an integrative approach to DNA repair. In fact,repair enzymes were elucidated; all or nearly all of the
human repair systems were reconstituted with purified the vast majority of repair systems are conserved be-
tween the prokaryotes and eukaryotes at the level ofproteins, and the crystal structures of a number of repair
enzymes were solved. In addition, the molecular mecha- gene sequence, protein structure, reaction mechanism,
and physiological role. The two notable exceptions arenism of transcription-coupled repair in E. coli was
solved, and the intimate relationship between transcrip- nucleotide excision repair and double-strand break re-
pair. However, even though in these two systems genetion and repair in eucaryotes was brought into sharp
focus. Similarly, in this decade important progress has sequence homologies are either minimal or not existent,
the reaction mechanisms, by and large, are conservedbeen made in identifying the genes and proteins in-
volved in repair of double strand breaks and establishing between prokaryotes and eukaryotes. Hence, to present
either mismatch repair (where the genes and the reac-in vitro systems for double strand break repair. Finally,
the DNA damage response checkpoints have been iden- tion mechanisms are conserved among bacteria, yeast,
humans) and nucleotide excision repair (where thetified in yeast, and in mammalian cells a number of the
key players have been isolated. It is quite likely that genes are not conserved between E. coli, and yeast and
humans but the basic reaction mechanism is) in threebefore the end of the decade a precise molecular de-
scription of the events leading from DNA damage to cell separate chapters causes unnecessary redundancy
and, more seriously, gets in the way of making unifyingcycle arrest will be understood in exquisite molecular
detail. models, which is the ultimate goal in science. Enough
said in the way of criticism.In addition to these advances of fundamental nature,
in the 1990s, important progress was made in the area Despite its faults, I find this two-volume set to be a
refreshing contribution to a fast moving field. First ofof human health and DNA repair. In the early 1990s,
it was discovered that defects in the mismatch repair all, the two books are very up to date, covering the field
through the end of 1997. The standard reference booksystem give rise to hereditary nonpolyposis colon can-
cer. Recently, evidence has been accumulating that de- on the topic, DNA Repair and Mutagenesis by E. Fried-
berg, G. Walker, and W. Siede (ASM Press), was pub-fective mismatch repair may also give rise to resistance
to some commonly used anticancer drugs. Finally, this lished in early 1995 and many important discoveries
were made within the four-year span that separates thepast year, work on DNA photolyase, which has been
considered an oddity not just by the molecular biology two books. The editors ought to be congratulated for
managing to obtain up-to-date chapters from nearly allcommunity at large but even by the repair community
itself, has led to the discovery of the circadian photore- contributors. Second, the commonly made criticism of
multiauthored books such as this, that the chapters areceptor in man, mouse, and flies. Against this backdrop,
then, it was fitting that this fall I received in the mail a of uneven quality, does not apply to this two-volume
set. In fact, in this case, I consider the multiauthorshipnumber of books on DNA repair, including the two-vol-
ume set DNA Damage and Repair by J. A. Nickoloff and a major strength of this book. There are chapters written
by postdocs, by young assistant professors, and byM.F. Hoekstra, which is the subject of this review. This
is an excellent book with many outstanding features and veterans who have been in the repair field from the time
of its inception. Some are overly enthusiastic, some arefew shortcomings. The two-volume set covers virtually
the entire field of DNA repair research. I will critique the very matter-of-fact, and some are reflective. However,
without exception, I found all chapters informative andrelatively few deficiencies of the book before comment-
ing on its virtues, which are many. well written, and I enjoyed reading them. The varying
styles, emphases, and backgrounds of the contributorsThe shortcomings include the following. First, even
though the title is ªDNA Damage and Repairº there is add a distinct flavor to the book that I find rather re-
freshing.very little on causes and mechanisms of DNA damage.
Second, some important topics, most notably adaptive It is difficult to single out one chapter that stands
above all others because they are all well written andresponse to alkylation damage and the OxyR-mediated
oxidative response reaction, are not covered. Third, al- current. However, I do have favorites. The chapter on
ªTranscription Repair Coupling in E. coliº in Volume 1though the organization is logical for the most part, at
times the juxtaposition of topics seems to be random. stands out in its generosity of spirit and its clarity of
presentation of a rather complex subject. In Volume 2,For example in Volume 1, transcription±repair coupling
is sandwiched between ªDouble-Strand Break Repairº chapter 15, which deals with gene activation by geno-
toxic stress, and chapter 19, on cellular responses toand ªBranched DNA Resolving Enzymes.º Finally, and
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DNA damage and human chromosome instability syn- in cancer trickled out (actually a relatively short period
in the timeframe of translating a new concept to actualdromes, are informative and well balanced between
clinical development). In this first decade, antigen tar-facts and models. The latter two chapters also point to
gets on cancer cells had to be identified and sufficientimportant future directions of DNA repair research: the
quantities of clinical grade antibodies needed to be pro-connections among DNA damage, repair intermediates,
duced, accomplished largely in these early years in aca-and signaling and execution of DNA damage check-
demic laboratories with relatively small budgets. Aspoints.
sometimes happens with new cancer therapies, initialThese books should be of value to anyone interested
clinical trials fueled optimism when objective tumor re-in DNA repair. They are written so as to be accessible
gressions were observed in selected patients with lym-to molecular biologists and cancer researchers ranging
phoma (Miller, 1982) and solid tumors (Houghton, 1985).from enzymologists to oncogene and tumor suppressor
However substantial problems were also identifiedhunters, to clinical oncologists. Naturally, all DNA repair
(Scheinberg and Houghton, 1987). These included, amongresearchers, whether they are first-year graduate stu-
others: (1) immunogenicity of mAbs, leading to resis-dents or professors, may greatly benefit from this book.
tance and rapid clearance of antibodies from the body;I recommend the book highly and congratulate the edi-
(2) difficulties of targeting antibodies, which are fairlytors and authors for a job well done.
large protein molecules, into tissues especially into solid
tumors; (3) a perceived need to increase potency ofAziz Sancar
tumor destruction by conjugating nuclides, toxins, andDepartment of Biochemistry and Biophysics
other virulent molecules to mAbs; and (4) the increas-University of North Carolina School of Medicine
ingly high cost of producing clinical grade mAbs. A newChapel Hill, North Carolina 27599
jargon emerged among the cognicenti in the mAb field,
including RIT (radioimmunotherapy), HAMA (human
anti-mouse antibodies), HARA (human anti-ricin anti-
bodies), and the laughable term HAHA (human anti-
Raising Monoclonal Antibodies humanized antibody).
In this first decade, enthusiasm and expectations
were high, energized further by preliminary results withMonoclonal Antibody±Based Therapy of Cancer
other biologic agents including interleukin-2, erythropoi-Edited by Michael L. Grossbard
etin, and granulocyte colony±stimulating factor. How-New York: Marcel Dekker (1998). 464 pp. $185.00
ever the problems identified in the early clinical trials
were substantial and stalled further clinical developmentWhile growing up, my father constantly reminded me
into the 1990s. These teen years were difficult: the reac-that patience was a virtue. He was presumably reacting
tion from the medical community, pharmaceutical indus-to the impetuous nature of children. These childhood
try, and public was swift and stern. The lack of rapidtraits often serve scientists well, driving creativity and
advancement of early phase I clinical trials to phase IIIpushing new frontiers. However, translating new discov-
trials (where efficacy of treatments is established in or-eries to improve the human condition is a different kettle
der to obtain approval to market a new treatment) was
of fish, rarely leading to instant gratification. More often
interpreted as failure. In particular, quantities of mAb
than not, clinical research requires persistence, durabil-
were limited, frustrating more incisive clinical trials.
ity, and some luck. However, the problems that were identified also had
Monoclonal antibodies (mAbs) burst onto the scene potential solutions. The problems of immunogenicity
in 1975 with the report by Kohler and Milstein (1975) could be overcome at least partially by engineering ªhu-
that somatic cell hybridization could be used to rescue manizedº mAbs. Penetration into solid tumors might
and immortalize B cells secreting immunoglobulins of be improved by miniaturizing the antibody. An array of
defined specificities. The implications were quickly rec- nuclides, drugs, and toxins appeared that might in-
ognized. Many variations on this general theme fol- crease potency. It was too early to declare the demise of
lowed, such as phage displays and engineering better mAbs for the treatment of cancer. Further development
antigen-binding sites. The application of mAbs as re- required substantial resources, which were provided by
agents in experimental laboratories steadily emerged several perceptive biotechnology and pharmaceutical
over several decades, now typically consuming increas- companies.
ing proportions of laboratory budgets. By the mid-1990s, mAbs were quietly moving out of
In the early, heady days after the original Kohler and their adolescent identity crisis to become real treat-
Milstein report, it was hoped that mAbs would quickly ments. In cancer therapy, reports of clinical responses
emerge as treatments for diseases. This hope was par- after mAb treatments in patients with lymphoma became
ticularly attractive for cancer where new therapies are more frequent. One mAb, Rituxan, directed against the
meager and ªsuccessfulº new treatments usually involve CD20 B cell differentiation antigen (McLaughlin, 1998)
small increments in efficacy. Here was a way to poten- was approved in 1997 by the FDA for treatment of pa-
tially target molecules on cancer cells, using mAbs as tients with relapsed or refractory low2grade or follicular
ªsilver bullets,º ªguided missiles,º or my personal favor- B cell lymphomas, and other mAb-based treatments for
ite ªtumor-seeking A bomb.º Perhaps this would open lymphoma may follow shortly. In 1998, the FDA ap-
an era of rationally designed, targeted therapies against proved Herceptin, an mAb directed against the HER2/
cancer. neu surface protein overexpressed on metastatic can-
However, it took 5±10 years after the Kohler and cers in 25%±30% of women with breast carcinoma. Her-
ceptin improved response rates in combination with theMilstein report before the results of the first clinical trials
